Clinical trials: Risk Factor
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Cystoid Macular Edema
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the…
- Trial name
- NCT03025945
- Testing
- Nepafenac 0.3%, Saline Solution
- Volunteers
- 662 people
- Sponsor
- Intuor Technologies, Inc.
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Cardiovascular Disease, Coronary Disease
Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors
The purpose of this trial are to pragmatically investigate whether participation in a comprehensive CR (i.e., exercise with education) program in a Latin American MIC results in better functional capacity, cardiovascular risk…
- Trial name
- NCT02575976
- Testing
- comprehensive CR, exercise-based CR, wait list control
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Federal University of Minas Gerais
Diabetes
Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus
Dental implants are regarded as a standard of care in restoring missing teeth. Although there is a high prevalence of diabetics who receive dental implants, the relationship between dental implants and diabetes has not clearly…
- Trial name
- NCT00933491
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Hyperlipidemia, Hypertension
Medication Adherence Clinical Decision Support
More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States.
- Conditions
- Hyperlipidemia, Hypertension, Diabetes, Medication Nonadherence
- Trial name
- ADH-Wizard (NCT03748420)
- Testing
- Adherence Intervention
- Where
- United States
- Volunteers
- 5,421 people
- Sponsor
- HealthPartners Institute
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Adenocarcinoma of the Prostate
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they…
- Trial name
- NCT01832259
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Obesity, Risk Factors
Motivational Interviewing to Promote Healthy Behaviours in Young Adults
The overall goals of this project are to evaluate the feasibility of web-based nurse-led motivational interviewing and educational interventions to promote healthy behaviours for obesity prevention and maintenance of healthy…
- Trial name
- Motivate (NCT05264740)
- Testing
- Motivational interviewing, Educational materials
- Where
- Canada
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- McMaster University
Fracture Fixation, Intramedullary, Surgical Wound Infection
Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures
Diaphyseal femoral and tibial fractures are in the spotlight within the traumatology-orthopedics scenario. Intramedullary nailing (IMN) remains the method of choice for treating these fractures, both open and closed ones.
- Trial name
- NCT03148067
- Testing
- Intramedullary nailing for fracture fixation
- Volunteers
- 225 people
- Sponsor
- University of Sao Paulo
Asthma
Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients
The purpose of this study is to assess the predictive ability of three asthma risk markers: the ratio of controller medication to total asthma medication, an albuterol only marker, and an oral corticosteroid use marker, as well…
- Trial name
- NCT01346852
- Testing
- Asthma treatment with an asthma-related medication and at least one asthma controller medication
- Volunteers
- 101,437 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Risk Factor
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.
- Trial name
- COSETTE (NCT04731363)
- Testing
- xylitol, 30g, erythritol, 30g, xylitol, 5g
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, High Blood Pressure
Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support
The objective of this study is to compare the effectiveness of a novel program-Family Support for Health Action (FAM-ACT) - to individual patient-focused diabetes self-management education and support (I-DSMES).
- Conditions
- Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
- Trial name
- NCT03812614
- Testing
- FAM ACT, I-DSMES
- Where
- 2 sites in United States
- Volunteers
- 444 people
- Sponsor
- University of Pittsburgh
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Myelodysplastic Syndromes
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00503880
- Testing
- filgrastim, clofarabine, cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Cardiovascular Risk Factor
Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity
Our goal is to develop personalized decision rules for selecting the frequency, timing, and content of messages to promote physical activity.
- Trial name
- RandomAIM (NCT03907683)
- Testing
- Short Message with Text and Optional Image
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Penn State University
Cardiovascular Diseases, Hypercholesterolemia
Vascular Lifestyle-Intervention and Screening in Pharmacy
The overall goal of the present project is to contribute to new knowledge about the effect of a low threshold population screening system for cardiovascular risk factors in Norway.
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Dyslipidemia, Hypertensive Disease
- Trial name
- VISA (NCT02223793)
- Testing
- Information on high risk factor levels and lifestyle advice, No information on high risk factor levels but lifestyle advice, No information on high risk factor levels, nor lifestyle advice
- Where
- Norway
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Cardiovascular Risk Factor, Cardiovascular Diseases
Effects of Breaking up Prolonged Sitting on Postprandial Cardiometabolic Disease Risk Markers in South Asian Adults
The purpose of this study is to examine whether breaking up prolonged sitting with short regular bouts of walking can reduce blood sugar and cholesterol levels after eating, which are risk markers for Type 2 diabetes and heart…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Physical Activity
- Trial name
- NCT03898206
- Testing
- Breaking up sitting with walking breaks (INT-SIT), Prolonged sitting (SIT)
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Hypertension
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular…
- Trial name
- NCT00936208
- Where
- 120 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 3,184 people
- Sponsor
- Boehringer Ingelheim